Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Reports Q4 revenue $$15.04M, consensus $6.2M. “Spero is focused on the execution of the tebipenem HBr clinical program, including preparing for ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. The latest program to be discontinued is SPR206, a next-gen polymyxin ...

After the first three tickets were punched for this week's Final Four, the final spot in the national semifinals will be ...

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ...

Spero Therapeutics SPRO is gearing up to announce its quarterly earnings on Thursday, 2025-03-27. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

The latest price target for Spero Therapeutics (NASDAQ:SPRO) was reported by HC Wainwright & Co. on January 30, 2025. The analyst firm set a price target for $5.00 expecting SPRO to rise to within ...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...

The Local Government and Social Care Ombudsman (LGO) found the pair suffered "injustice". An authority spokesperson said it accepted that the case "did not meet the high standards we strive for ...